Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new ...

The approval was based on the therapy’s safety and efficacy data, including muscle health and longer-term functional outcomes ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has released new data from its ENDEAVOR study, showing encouraging results for its Duchenne muscular dystrophy treatment, ELEVIDYS.

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ ... for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan.

ELEVIDYS is indicated in U.S. for the treatment of Duchenne muscular dystrophy (DMD ... You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).